Biomarkers to Predict CRT Response in Patients With HF (BIOCRT) (BIOCRT)

• ClinicalTrials.gov Identifier: NCT01949246
• Recruitment Status: Unknown
• First Posted: September 24, 2013
• Last Update Posted: January 30, 2015
• Sponsor: Massachusetts General Hospital
• Information provided by (Responsible Party): Jagmeet Singh, Massachusetts General Hospital

Study Description

Brief Summary:

The prospective study aims:

1. To determine the role and mechanism of biomarkers for prediction of response to CRT
2. To determine the role of biomarkers and their effect on left ventricular remodeling in patients undergoing CRT.

Condition or disease
Heart Failure

Detailed Description:

Cardiac resynchronization therapy (CRT) with biventricular pacing has emerged as a novel treatment for congestive heart failure (CHF) not responsive to optimal drug therapy. CRT is associated with significant improvements in hemodynamics and functional status of patients with CHF. The physiologic effect of CRT is achieved via placing electrical leads in the right and left ventricular walls, and synchronizing ventricular contraction. Over time, this leads to ventricular wall reverse remodeling, and sustained improvements in left ventricular ejection fraction (EF).

Currently, the indications for CRT include end-stage heart failure class II-IV with an EF < 35%, and a QRS duration > 120ms. The QRS duration is used as an indicator of the degree of ventricular electromechanical dyssynchrony, however, a growing number of studies have postulated its inability to predict response to therapy. As a result, other measures of mechanical dyssynchrony are being sought to guide therapy. The vast majority of these studies have examined clinical, cardiac, electrocardiographic, and device-specific indices, however, a widely accepted predictor of response to CRT is lacking.

CRT results in electromechanical synchrony, leading to an improved ejection fraction, exercise tolerance, and reduction of symptoms. Although electrical re-synchronization and intra-procedural hemodynamic improvement are achieved after the device is implanted, the sustained clinical improvement is likely due to ventricular reverse remodeling. A major issue with CRT is that approximately a third of patients receiving devices do not achieve improved clinical or functional status, and fail to undergo changes in ventricular geometry, and ventricular remodeling. It remains unknown whether this is due to abnormalities in the factors involved in lead placement or procedural strategies, geometric remodeling, alterations in cardiac energy metabolism, supply of energy (i.e. coronary blood flow), or inappropriate/inadequate microvascular proliferation.

This study will evaluate a series of biochemical markers implicated in pathophysiology of heart failure, in predicting response to CRT with biventricular pacing.

Study Design

• Study Type: Observational
• Estimated Enrollment: 496 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Analysis of Circulating Biomarkers in Predicting Response to Cardiac Resynchronization Therapy (CRT) With Biventricular Pacing in Patients With Congestive Heart Failure (BIOCRT)
• Study Start Date: September 2007
• Estimated Primary Completion Date: January 2016
• Estimated Study Completion Date: January 2016

Groups and Cohorts

Group/Cohort
CRT patients; Patients undergoing CRT device implantation
Healthy patients; Healthy controls

Outcome Measures

Primary Outcome Measures :

1. MACE [ Time Frame: 2 years ]
   death, HF hospitalization, left ventricular assist device, heart transplant

Secondary Outcome Measures :

1. CRT clinical response [ Time Frame: 6 months ]
   For the definition of a positive response to CRT, patients will be classified according to the HF Clinical Composite Score (CCS). Responders will be defined as those with improved CCS from baseline to 6 month follow-up. Those not meeting this criterion will be considered nonresponders. An outcome panel consisting of two cardiologists will determine the clinical response of each subject based on review of the medical record. If there is disagreement in the assessment of either baseline or follow-up CCS amongst the two cardiologists, a third cardiologist will adjudicate the case.

Biospecimen Retention:   Samples With DNA

Whole Blood

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes
• Sampling Method: Probability Sample

Study Population

Outpatient or inpatient heart failure patients scheduled for CRT implantation

Criteria

Inclusion Criteria:

• Study participant with an approved indication for a CRT or CRT-D system.

  1. New York Heart Association (NYHA) Class II, III, or IV Heart Failure unresponsive to drug therapy.
  2. EF < 35%.
  3. QRS width > 120 ms.
• Study participant receiving optimal medical therapy including ACE inhibitor or Angiotensin Receptor Blocker (ARB), Beta-Blocker, and Diuretic.
• Study participants with a history of significant congestive decompensation events within the last 12 months.

Exclusion Criteria:

• NYHA Class I Heart Failure.
• Co morbidities (e.g., cancer), which may limit lifespan < 6 months.
• Severe aortic stenosis (valve area < 1.0 cm2).
• Study participants that received cardiac surgery or intervention (i.e. coronary artery bypass grafting (CABG), valve surgery, angioplasty, arthrectomy) within the preceding 90 days.
• Study participants with moderate to severe chronic obstructive pulmonary disease (COPD), defined as needing chronic oxygen therapy or recent hospitalization (within 30 days) for COPD flare up.
• Concurrent pregnancy.
• Study participants with primary pulmonary hypertension.
• Study participants on continuous or intermittent infusion therapy for heart failure.

Contacts and Locations

Contacts

Contact: Jagemeet P Singh, MD PHD; 617-726-4662; jsingh@partners.org

Locations

United States, Massachusetts

Massachusetts General Hospital; Recruiting

Boston, Massachusetts, United States, 02114

Contact: Jagmeet P Singh, MD PHD 617-726-4662 jsingh@partners.org

Principal Investigator: Jagmeet P Singh, MD PHD

Sponsors and Collaborators

Massachusetts General Hospital

Investigators

• Principal Investigator: Jagmeet P Singh; Massachussetts General Hospital
• Principal Investigator: Quynh A Truong, MD MPH; Weill Medical College of Cornell University

More Information

Publications of Results:

Truong QA, Januzzi JL, Szymonifka J, Thai WE, Wai B, Lavender Z, Sharma U, Sandoval RM, Grunau ZS, Basnet S, Babatunde A, Ajijola OA, Min JK, Singh JP. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study. Heart Rhythm. 2014 Dec;11(12):2167-75. doi: 10.1016/j.hrthm.2014.07.007. Epub 2014 Jul 8.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ajijola OA, Chatterjee NA, Gonzales MJ, Gornbein J, Liu K, Li D, Paterson DJ, Shivkumar K, Singh JP, Herring N. Coronary Sinus Neuropeptide Y Levels and Adverse Outcomes in Patients With Stable Chronic Heart Failure. JAMA Cardiol. 2020 Mar 1;5(3):318-325. doi: 10.1001/jamacardio.2019.4717.

Bakos Z, Chatterjee NC, Reitan C, Singh JP, Borgquist R. Prediction of clinical outcome in patients treated with cardiac resynchronization therapy - the role of NT-ProBNP and a combined response score. BMC Cardiovasc Disord. 2018 Apr 24;18(1):70. doi: 10.1186/s12872-018-0802-8.

• Responsible Party: Jagmeet Singh, Jagmeet P Singh, M.D. Ph.D., Massachusetts General Hospital
• ClinicalTrials.gov Identifier: NCT01949246
• Other Study ID Numbers: 2007P001921
• First Posted: September 24, 2013
• Last Update Posted: January 30, 2015
• Last Verified: January 2015

Keywords provided by Jagmeet Singh, Massachusetts General Hospital:

Biomarkers

Additional relevant MeSH terms:

Heart Failure; Heart Diseases; Cardiovascular Diseases